Date: 2017-08-25
Type of information: Research agreement
Compound: new small molecule-based therapeutics using ESAC platform and DNA-Encoded Chemistry technology
Company: Philogen (Italy) Servier (France)
Therapeutic area: Technology - Services
Type agreement: research - R&D
Action mechanism: ESAC platform and DNA-Encoded Chemistry technology were developed by Philochem scientists in collaboration with the group of Prof. Dario Neri at ETH Zurich. These two discovery technologies allow to screen up to billions small molecules compounds in a very fast and efficient manner, and to further optimize the hit compounds in a fully automatic, DNA-tagged, fragment-based drug discovery manner.
Disease:
Details:
Financial terms: No financial details of the agreement were released.
Latest news:
